Psychosis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psychosis - Pipeline Review, H2 2016, provides an overview of the Psychosis (Central Nervous System) pipeline landscape.

Psychosis is a serious mental disorder characterized by thinking and emotions that are so impaired, that they indicate that the person experiencing them has lost contact with reality. Psychotic symptoms include disorganized thought, speech or behavior, disordered thinking (jumping between unrelated topics, making strange connections between thoughts), Catatonia (unresponsiveness). Treatment includes antipsychotic drugs, which reduce hallucinations and delusions and improve thinking and behavior are helpful, whether the cause is a medical or psychiatric disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psychosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psychosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psychosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15 and 1 respectively for Psychosis.

Psychosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Psychosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Psychosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psychosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psychosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psychosis (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psychosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psychosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Psychosis Overview 8
Therapeutics Development 9
Pipeline Products for Psychosis - Overview 9
Psychosis - Therapeutics under Development by Companies 10
Psychosis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Psychosis - Products under Development by Companies 13
Psychosis - Companies Involved in Therapeutics Development 14
Acadia Pharmaceuticals Inc. 14
Addex Therapeutics Ltd 15
Evotec AG 16
Gabather AB 17
Glenmark Pharmaceuticals Ltd. 18
Heptares Therapeutics Limited 19
Integrative Research Laboratories Sweden AB 20
Merck & Co., Inc. 21
Newron Pharmaceuticals S.p.A. 22
Reviva Pharmaceuticals Inc. 23
Sumitomo Dainippon Pharma Co., Ltd. 24
Sunovion Pharmaceuticals Inc. 25
Psychosis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 33
ADX-88178 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CB-0306 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
evenamide - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
GT-001 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GT-002 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
GT-004 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
GT-006 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HUF-101 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
IRL-790 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
pimavanserin tartrate - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RP-5063 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
SEP-39 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule for Psychosis - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Psychosis - Dormant Projects 60
Psychosis - Discontinued Products 61
Psychosis - Product Development Milestones 62
Featured News & Press Releases 62
May 31, 2016: ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis 62
Apr 29, 2016: FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease 62
Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals' NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson's Disease Outweigh the Risks 63
Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson's Disease Psychosis 64
Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch 64
Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson's Disease Psychosis 65
Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin 65
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 66
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 67
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 67
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for Psychosis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H2 2016 14
Psychosis - Pipeline by Addex Therapeutics Ltd, H2 2016 15
Psychosis - Pipeline by Evotec AG, H2 2016 16
Psychosis - Pipeline by Gabather AB, H2 2016 17
Psychosis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 18
Psychosis - Pipeline by Heptares Therapeutics Limited, H2 2016 19
Psychosis - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 20
Psychosis - Pipeline by Merck & Co., Inc., H2 2016 21
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 22
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 23
Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 24
Psychosis - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 32
Psychosis - Dormant Projects, H2 2016 60
Psychosis - Discontinued Products, H2 2016 61